ATE280823T1 - Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren - Google Patents

Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Info

Publication number
ATE280823T1
ATE280823T1 AT99403194T AT99403194T ATE280823T1 AT E280823 T1 ATE280823 T1 AT E280823T1 AT 99403194 T AT99403194 T AT 99403194T AT 99403194 T AT99403194 T AT 99403194T AT E280823 T1 ATE280823 T1 AT E280823T1
Authority
AT
Austria
Prior art keywords
inactivation
adenoviruses
viral preparation
preparation
virus
Prior art date
Application number
AT99403194T
Other languages
English (en)
Inventor
David Gaillac
Michel Koehl
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE280823T1 publication Critical patent/ATE280823T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AT99403194T 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren ATE280823T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816147A FR2787465A1 (fr) 1998-12-21 1998-12-21 Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes

Publications (1)

Publication Number Publication Date
ATE280823T1 true ATE280823T1 (de) 2004-11-15

Family

ID=9534248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99403194T ATE280823T1 (de) 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Country Status (11)

Country Link
US (2) US7026154B1 (de)
EP (1) EP1016711B1 (de)
JP (1) JP4459353B2 (de)
AT (1) ATE280823T1 (de)
AU (1) AU769121B2 (de)
CA (1) CA2292922C (de)
DE (1) DE69921435T2 (de)
DK (1) DK1016711T3 (de)
ES (1) ES2230820T3 (de)
FR (1) FR2787465A1 (de)
PT (1) PT1016711E (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003014338A1 (ja) * 2001-08-02 2004-11-25 アンジェスＭｇ株式会社 不活性化ウイルスエンベロープの製造方法
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
PT2382474E (pt) 2009-01-20 2015-06-03 Transgene Sa Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
BRPI1009892A2 (pt) 2009-03-24 2016-03-15 Transgène S A método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
BRPI1010512A2 (pt) 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
EP2452194B1 (de) 2009-07-10 2015-11-11 Transgene SA Biomarker zur patientenauswahl und entsprechende verfahren
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EP3188816B1 (de) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatographie-medum, bestehend aus diskreten porösen bündeln von nanofibrillen
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US11690869B2 (en) * 2020-04-23 2023-07-04 Johnson & Johnson Consumer Inc. Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378208B2 (de) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Verfahren zur Herstellung einer Protein enthaltenden Zusammensetzung
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
IL130198A (en) * 1996-12-13 2005-09-25 Schering Corp Methods for purifying viruses
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren

Also Published As

Publication number Publication date
US20060166345A1 (en) 2006-07-27
JP4459353B2 (ja) 2010-04-28
EP1016711A1 (de) 2000-07-05
FR2787465A1 (fr) 2000-06-23
DK1016711T3 (da) 2005-03-07
US7026154B1 (en) 2006-04-11
JP2000201673A (ja) 2000-07-25
ES2230820T3 (es) 2005-05-01
AU6535899A (en) 2000-06-22
EP1016711B1 (de) 2004-10-27
CA2292922A1 (fr) 2000-06-21
CA2292922C (fr) 2011-05-31
DE69921435D1 (de) 2004-12-02
PT1016711E (pt) 2005-02-28
AU769121B2 (en) 2004-01-15
DE69921435T2 (de) 2006-03-02
US7378265B2 (en) 2008-05-27

Similar Documents

Publication Publication Date Title
DE69921435D1 (de) Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
DE3680130D1 (de) Verfahren zur vireninaktivierung in gamma-globulin durch waermebehandlung.
DE59501599D1 (de) Verfahren zur Herstellung von Propandiol-1,2
DE69201952D1 (de) Verwendung eines enzymhaltigen granulates und verfahren zur herstellung von einem pelletisierten futter.
EP0864646A3 (de) Verfahren zur Inaktivierung von lipidumhüllten Viren
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE69526182D1 (de) Verfahren zur Herstellung von Trehalosederivaten
DE69325948D1 (de) Entfernung von Antikörpern aus von Blut stammenden Zusammensetzungen unter Erhalt von Gerinnungsfaktoren
DE69514865D1 (de) Verfahren zur Herstellung von L-Asparaginsäure
DE69432158D1 (de) Verfahren zur Herstellung von optisch aktiven 2-Amino-1-phenylethanol Derivaten
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
GB1488774A (en) Hepatitis b antigen and method of producing it
DE69005542D1 (de) Verfahren zur Herstellung von 3-Pentensäure.
ATE71110T1 (de) Verfahren zur reinigung eines proteins.
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE59502572D1 (de) Verfahren zur Herstellung von 2-Halogenpyridinaldehyden
FI880636A7 (fi) Menetelmä vaipallisten virusten inaktivoimiseksi solun avulla in vitro valmistetuissa proteiinivalmisteissa.
DE59004380D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten und neue 1,1-Difluor-2-halogenethyl-(halogen) methyl-ketone.
DE69109243D1 (de) Verfahren zur Herstellung von L-Tryptophan und L-Threonine.
DE59309002D1 (de) Verfahren zur Herstellung von 6-Chlor-(6H)-dibenz-(c,e)(1,2)-oxaphosphorin
DE69019843D1 (de) Verfahren zur Herstellung von NADH-Oxydase.
DE59500712D1 (de) Verfahren zur Herstellung von 4,6-Diaminoresorcin
ATE74162T1 (de) Verfahren zur erhaltung und vermehrung von defekten, nicht-infektioesen virusgenomen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1016711

Country of ref document: EP